High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma

World Journal of Gastroenterology

Volumn 21, Issue 11, 2015, Pages 3256-3265

  Xu, Yun Fei ^a   Ge, Fu Jun ^b   Han, Bo ^c   Yang, Xiao Qing ^c   Su, Hong ^c   Zhao, An Cheng ^d   Zhao, Ming Hong ^d   Yang, Yu Bao ^b   Yang, Jie ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Pharmacy   (China)

^c SHANDONG UNIVERSITY   (China)

^d Yishui Central Hospital   (China)

Author keywords

Epithelial mesenchymal transition; High mobility group box 1; Intrahepatic cholangiocarcinoma; Lymphatic microvessel density; Vascular endothelial growth factor C

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN C; VIMENTIN; HMGB1 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER; VEGFC PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CAPILLARY DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MODULATION; NONHUMAN; OVERALL SURVIVAL; PERINEURAL INVASION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; BILE DUCT TUMOR; CHI SQUARE DISTRIBUTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LYMPH VESSEL; LYMPHANGIOGENESIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RNA INTERFERENCE; SECONDARY; TIME; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84925634340     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i11.3256     Document Type: Article

References (42)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-125 [PMID: 15192785 DOI: 10.1055/s-2004-828889]
2. Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, Goldin S, Rosemurgy P, Rosemurgy AS. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004;70:743-748; discussion 748-749 [PMID: 15481288]
3. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, De Matteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96 [PMID: 18580211 DOI: 10.1097/SLA.0b013e318176c4d3]
4. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010;42:253-260 [PMID: 20097142 DOI: 10.1016/j.dld.2009.12.008]
5. Van Beijnum JR, Nowak-Sliwinska P, Van Den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2013;32:363-374 [PMID: 22391561 DOI: 10.1038/onc.2012.49]
6. Ellerman JE, Brown CK, De Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-2848 [PMID: 17504981 DOI: 10.1158/1078-0432. CCR-06-1953]
7. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342 [PMID: 15803152 DOI: 10.1038/nri1594]
8. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003;23:2991-2998 [PMID: 12665595]
9. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170 [PMID: 11793367 DOI: 10.1002/path.1031]
10. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751-760 [PMID: 15743787 DOI: 10.1016/S0002-9440 (10) 62296-1]
11. Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A. HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer 2013;2013:157103 [PMID: 23766911 DOI: 10.1155/2013/157103]
12. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008;216:167-175 [PMID: 18680137 DOI: 10.1002/path.2391]
13. Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001;20:4762-4773 [PMID: 11532940 DOI: 10.1093/emboj/20.17.4762]
14. Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, Kuniyasu H. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010;77:17-23 [PMID: 20185963 DOI: 10.1159/000272950]
15. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, Ohmori H, Luo Y, Yasui W, Bosserhoff AK, Kuniyasu H. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008;99:1806-1812 [PMID: 18616526 DOI: 10.1111/j.1349-7006.2008.00894.x]
16. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011;8:428-439 [PMID: 21691304 DOI: 10.1038/nrurol.2011.85]
17. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829 [PMID: 18539112 DOI: 10.1016/j.devcel.2008.05.009]
18. Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol 2013;183:1654-1666 [PMID: 24160326 DOI: 10.1016/j.ajpath.2013.07.029]
19. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256 [PMID: 11733374 DOI: 10.1016/S0002-9440 (10) 63075-1]
20. Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J, Han B. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 2013;16:301-307 [PMID: 23917306 DOI: 10.1038/pcan. 2013.25]
21. Moser B, Janik S, Schiefer AI, Müllauer L, Bekos C, Scharrer A, Mildner M, Rényi-Vámos F, Klepetko W, Ankersmit HJ. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS One 2014;9:e94118 [PMID: 24705787 DOI: 10.1371/journal.pone.0094118]
22. Weng H, Deng Y, Xie Y, Liu H, Gong F. Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer 2013;13:311 [PMID: 23803172 DOI: 10.1186/1471-2407-13-311]
23. Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, Su H, Sun X, Liu Z, Zhang J, Qin X, Han B. Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep 2014;32:700-708 [PMID: 24927194 DOI: 10.3892/or.2014.3261]
24. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8 [PMID: 1701519 DOI: 10.1056/NEJM199101033240101]
25. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, De Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-1579 [PMID: 12142044]
26. Hall FT, Freeman JL, Asa SL, Jackson DG, Beasley NJ. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:716-719 [PMID: 12874070 DOI: 10.1001/archotol.129.7.716]
27. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann H. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007;33:1025-1029 [PMID: 17400419 DOI: 10.1016/j.ejso.2007.02.020]
28. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39:220-229 [PMID: 14752841 DOI: 10.1002/hep. 20031]
29. Fujita T. Analyzing risk factors for intrahepatic cholangiocarcinoma. Hepatology 2013;58:1862-1863 [PMID: 23609480 DOI: 10.1002/hep. 26448]
30. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008;40:446-452 [PMID: 18294942 DOI: 10.1016/j.dld.2007.11.024]
31. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384 [PMID: 20404851 DOI: 10.1038/ni.1863]
32. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009;7:38 [PMID: 19476625 DOI: 10.1186/1479-5876-7-38]
33. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001;21:3881-3885 [PMID: 11911263]
34. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100 [PMID: 15666359 DOI: 10.1002/pros.20219]
35. Chuangui C, Peng T, Zhentao Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res 2012;18:1021-1027 [PMID: 22544356 DOI: 10.1007/s12253-012-9539-3]
36. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008;28:1659-1666 [PMID: 18630523]
37. Van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-99 [PMID: 18264787 DOI: 10.1007/s10456-008-9093-5]
38. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-939 [PMID: 15210113 DOI: 10.1016/j.cell.2004.06.006]
39. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz I Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009;1:338-351 [PMID: 20049737 DOI: 10.1002/emmm.200900039]
40. Janda E, Litos G, Grünert S, Downward J, Beug H. Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway. Oncogene 2002;21:5148-5159 [PMID: 12140765 DOI: 10.1038/sj.onc.1205661]
41. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
42. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51 Suppl 6:VI1-VI9 [PMID: 12376491]